607 related articles for article (PubMed ID: 32134578)
41. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
Naveen R; Jain A; Muhammed H; Gupta L; Misra DP; Lawrence A; Agarwal V; Misra R; Aggarwal A
Rheumatol Int; 2021 Mar; 41(3):625-631. PubMed ID: 33388903
[TBL] [Abstract][Full Text] [Related]
42. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
43. Macrophage activation syndrome in an inadequately treated patient with systemic onset juvenile idiopathic arthritis.
Juneja M; Jain R; Mishra D
Kathmandu Univ Med J (KUMJ); 2009; 7(28):411-3. PubMed ID: 20502084
[TBL] [Abstract][Full Text] [Related]
44. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
[TBL] [Abstract][Full Text] [Related]
45. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
[TBL] [Abstract][Full Text] [Related]
46. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
[TBL] [Abstract][Full Text] [Related]
47. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
48. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.
Ambler WG; Nanda K; Onel KB; Shenoi S
Ann Med; 2022 Dec; 54(1):1839-1850. PubMed ID: 35786149
[TBL] [Abstract][Full Text] [Related]
49. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
[TBL] [Abstract][Full Text] [Related]
50. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.
Chantarogh S; Vilaiyuk S; Tim-Aroon T; Worawichawong S
BMC Nephrol; 2017 May; 18(1):159. PubMed ID: 28499374
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V; Klein A; Horneff G
Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
[No Abstract] [Full Text] [Related]
52. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.
Otar Yener G; Paç Kısaarslan A; Ulu K; Atalay E; Haşlak F; Özdel S; Bozkaya Yücel B; Gezgin Yıldırım D; Çakmak F; Öztürk K; Çakan M; Balık Z; Hasbal Akkuş C; Yıldız M; Erat T; Çetin BŞ; Yılmaz M; Bağlan E; Laçinel Gürlevik S; Atasayan V; Karadağ ŞG; Adrovic A; Çağlayan Ş; Tanatar A; Demirkan FG; Coşkuner T; Akgün Ö; Kasap Cüceoğlu M; Kavrul Kayaalp G; Şahin S; Başaran Ö; Demir F; Barut K; Çiftel M; Gürses D; Baykan A; Özsürekçi Y; Karagöz T; Sönmez HE; Bilginer Y; Aktay Ayaz N; Aydoğ Ö; Yüksel S; Sözeri B; Kasapçopur Ö; Özen S
Rheumatol Int; 2022 May; 42(5):879-889. PubMed ID: 34491393
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
[TBL] [Abstract][Full Text] [Related]
54. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Likhacheva TS; Isupova EA; Glebova NI; Kuchinskaya EM; Balbotkina EV; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Semin Arthritis Rheum; 2015 Feb; 44(4):417-22. PubMed ID: 25300700
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
56. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
57. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
58. Clinical profile and juvenile arthritis damage index in children with juvenile idiopathic arthritis: A study from a tertiary care center in south India.
Menon NVB; Peethambaran G; Puthiyapurayil AT; Nambudakath C; Arakkal R
Int J Rheum Dis; 2018 Apr; 21(4):871-879. PubMed ID: 27309679
[TBL] [Abstract][Full Text] [Related]
59. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
[TBL] [Abstract][Full Text] [Related]
60. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
